RxDoctor Payments Data

Josie Tanner, PA

Physician Assistant · Rome, GANPI 1831814409

Payments from drug & device makers

$3,629in general payments, 2019–2025

Across 232 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$691
  • Lilly USA, LLC$415
  • Novo Nordisk$316
  • GSK$235
  • Takeda Pharmaceuticals U.S.A., Inc.$215
  • Bayer$160
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$3,629100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,629 in reported general payments places this provider in the 85th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$4,685
Medicare patients
110
Services billed
241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide84$109,703
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$48,521
EliquisApixaban34$48,073
TrulicityDulaglutide19$31,879
JardianceEmpagliflozin19$28,067
FarxigaDapagliflozin Propanediol22$23,728
OzempicSemaglutide14$21,836
Soliqua 100-33Insulin Glargine/Lixisenatide13$13,704
JanuviaSitagliptin Phosphate17$11,987
LinzessLinaclotide13$9,873
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,065
VascepaIcosapent Ethyl11$3,669
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,320
Midodrine Hcl11$2,271
Gabapentin106$1,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$415$141,581103 claims
GSKTrelegy Ellipta, Anoro Ellipta$235$53,58650 claims
PfizerEliquis$142$48,07334 claims
Boehringer IngelheimJardiance$156$28,06719 claims
AstraZenecaFarxiga$156$23,72822 claims
Novo NordiskOzempic$316$21,83614 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$17$13,70413 claims
MerckJanuvia$41$11,98717 claims
AbbVieLinzess, Synthroid$691$11,45829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →